Biolingus IP GmbH
Development of sublingual delivery of peptides and proteins for chronic diseases
BioLingus is a Swiss biotech company spearheading the development of oral (sublingual) delivery of peptides and proteins for chronic diseases and immuno-therapy via our innovative formulation technology. Our company focuses on the development of products for treatment of metabolic diseases and various immuno-therapies.
Only registered users have access to funding information.
Please log in or register to continue. Registration is free.
03.07.2023
Biolingus files for IPO at Nasdaq (startupticker.ch)
08.09.2022
BioLingus and partners secure research grant for needle-free COVID-19 vaccine (startupticker.ch)
20.02.2019
BioLingus? partnership with Chinese Mega Pharma paves way for global expansion (startupticker.ch)
30.04.2018
Red Herrings Award for two Swiss life sciences startups (startupticker.ch)
No milestones
No Jobs
No videos and documents
No Awards
Biolingus IP GmbH
Development of sublingual delivery of peptides and proteins for chronic diseases
Headquarter:
Uhwiesen
Foundation Date:
July 2014
Technology:
- Biotech
Sectors:
- Biotech
- Protein drugs